Regional Medical Advisor
Alexion
Regional Medical Advisor
Alexion
Global biopharmaceuticals focusing on rare diseases
Introduction to role
The Regional Medical Advisor Pipeline (RMAP) is a vital part of Global DR&S, serving as a field-based scientific resource responsible for the external scientific engagement (ESE) strategy for designated programs within a Therapeutic Area (TA) in their region.
Collaborating closely with internal and external stakeholders, the RMAP will work on designated trials and cross-program scientific engagement needs. The RMAP will establish and maintain relationships with Key External Experts (KEEs) within a specific region to advise on Alexion’s clinical development strategy and trial execution within a TA.
Reporting directly to the Global TA Head of External Scientific Engagement for Hematology, Nephrology & Transplants (HNT), the RMAP will play a crucial role in ensuring the successful performance of clinical trials, supporting activities such as early insight collection, guiding feasibility, and enhancing trial recruitment and retention.
Accountabilities/Responsibilities
Essential Skills/Experience
Desirable Skills/Experience
Date Posted
30-Sep-2026Closing Date
Alexion is proud to be an Equal Employment Opportunity and Affirmative Action employer. We are committed to fostering a culture of belonging where every single person can belong because of their uniqueness. The Company will not make decisions about employment, training, compensation, promotion, and other terms and conditions of employment based on race, color, religion, creed or lack thereof, sex, sexual orientation, age, ancestry, national origin, ethnicity, citizenship status, marital status, pregnancy, (including childbirth, breastfeeding, or related medical conditions), parental status (including adoption or surrogacy), military status, protected veteran status, disability, medical condition, gender identity or expression, genetic information, mental illness or other characteristics protected by law. Alexion provides reasonable accommodations to meet the needs of candidates and employees. To begin an interactive dialogue with Alexion regarding an accommodation, please contact [email protected]. Alexion participates in E-Verify.
Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.
Explore more opportunities at Alexion